Evidence map›Paper›PMID 28669000›Full record

ReviewCurrent heart failure reports2017

Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic?

Lucas N L Van Aelst, Dominiek Mazure, Alain Cohen-Solal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Iron Deficiency and its Relationship with Chronic Heart Failure- A Review.Cardiovascular & hematological agents in medicinal chemistry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Lucas N L Van AelstDepartment of Cardiovascular Sciences, KU Leuven, Campus Gasthuisberg O&N1, Herestraat 49, box 911, 3000, Leuven, Belgium.
Dominiek MazureDepartment of Hematology, De Pintelaan 185, 9000, Ghent, Belgium.
Alain Cohen-SolalDepartment of Cardiology, Hôpital Lariboisière, 2 Rue Ambroise Paré, 75010, Paris, France. alain.cohen-solal@inserm.fr.
Ghent University Hospital · BEHôpital Lariboisière · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewHeart failure (HF) is a common, costly, disabling, and deadly clinical syndrome and often associated with one or several co-morbidities complicating its treatment or worsening its symptoms. During the last decade, iron deficiency (ID) got recognized as a frequent, debilitating yet easily treatable co-morbidity in HF. In this review, we focus on new evidence that emerged during the last 5 years and discuss the epidemiology, the causes, and the clinical consequences of ID in HF. RECENT

findingsApart from replenishing iron stores, intravenous iron improves patients' symptoms, perceived quality of life (QoL), exercise capacity, and hospitalization rates. These beneficial effects cannot be attributed to oral iron, as increased hepcidin levels, typical in inflammatory states such as HF, preclude resorption of iron from the gut. Intravenous iron is the only valid treatment option for ID in HF. However, there are several burning research questions and gaps in evidence remaining in this research field.

Indexed as

Anemia, Iron-DeficiencyComorbidityExercise ToleranceHeart FailureHepcidinsHumansInjections, IntravenousIronQuality of LifeHepcidinsIronAnemiaHeart failureIron deficiencyIron therapyPrognosis

Identifiers

PMID28669000
OpenAlexW2727272258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.